
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1197695/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	â€~Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax, 2021, 76, 396-398.	5.6	636
2	Post-Tuberculosis Infections and Chronic Lung Disease. , 2021, , 283-291.		0
3	Tuberculosis in People Living with HIV. , 2021, , 213-220.		0
4	Persistent TÂCell Repertoire Perturbation and TÂCell Activation in HIV After Long Term Treatment. Frontiers in Immunology, 2021, 12, 634489.	4.8	15
5	Contact tracing for SARS-CoV-2: what can be learned from other conditions?. Clinical Medicine, 2021, 21, e132-e136.	1.9	6
6	Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care. International Journal of Infectious Diseases, 2021, 113, S73-S77.	3.3	9
7	World Tuberculosis Day 2021 Theme — â€~The Clock is Ticking' — and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. International Journal of Infectious Diseases, 2021, 113, S1-S6.	3.3	10
8	Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study. European Respiratory Journal, 2021, 57, 2003831.	6.7	4
9	Improved treatment completion for tuberculosis patients: The case for a dedicated social care team. Journal of Infection, 2021, 82, e1-e3.	3.3	6
10	The high mental health burden of "Long COVID―and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. European Respiratory Journal, 2021, 57, 2004364.	6.7	62
11	Who gets a laboratory positive diagnosis of Mycoplasma pneumoniae: A 10-year retrospective analysis. Clinical Infection in Practice, 2021, 10, 100070.	0.5	1
12	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 349-359.	10.7	161
13	Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults. Vaccines, 2021, 9, 396.	4.4	7
14	Implementing and evaluating standardised tuberculosis incident management for nonhousehold contacts in a large clinical network. ERJ Open Research, 2021, 7, 00270-2021.	2.6	0
15	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature Communications, 2021, 12, 4385.	12.8	29
16	Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. BMJ Open, 2021, 11, e052885.	1.9	0
17	Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease. Lancet Respiratory Medicine,the, 2021, 9, 947-949.	10.7	3
18	The impact of COVID-19 on global tuberculosis control. Indian Journal of Medical Research, 2021, 153, 404-408.	1.0	0

#	Article	IF	CITATIONS
19	The impact of COVID-19 on global tuberculosis control. Indian Journal of Medical Research, 2021, 153, 404.	1.0	8
20	Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon-Î ³ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol. BMJ Open, 2021, 11, e050595.	1.9	0
21	Blood Transcriptomic Stratification of Short-term Risk in Contacts of Tuberculosis. Clinical Infectious Diseases, 2020, 70, 731-737.	5.8	66
22	Developing a pathway for the diagnosis and management of ocular tuberculosis. The pan-LOndon Ocular tuberculosis Pathway—LOOP. Eye, 2020, 34, 805-808.	2.1	13
23	Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort. Journal of Infectious Diseases, 2020, 221, 146-155.	4.0	29
24	Chest pain and a left parasternal soft tissue swelling in an immunocompetent refugee with disseminated tuberculosis. International Journal of Infectious Diseases, 2020, 90, 116-118.	3.3	2
25	Quantitative IFN-Î ³ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 984-991.	5.6	29
26	A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK. Journal of Infection, 2020, 80, 38-41.	3.3	8
27	Descriptive account of 18 adults with known HIV infection hospitalised with SARS-CoV-2 infection. Sexually Transmitted Infections, 2020, 97, sextrans-2020-054660.	1.9	5
28	Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study. European Respiratory Journal, 2020, 56, 2003498.	6.7	145
29	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine, 2020, 26, 1941-1949.	30.7	58
30	Urgent call for greater multilateralism and coordination of covid-19 trials. BMJ, The, 2020, 370, m2666.	6.0	0
31	Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK. BMJ Open Respiratory Research, 2020, 7, e000591.	3.0	14
32	Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy. EClinicalMedicine, 2020, 24, 100427.	7.1	4
33	Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. Journal of Antimicrobial Chemotherapy, 2020, 75, 3194-3201.	3.0	16
34	All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era. ERJ Open Research, 2020, 6, 00315-2020.	2.6	16
35	Cost effectiveness of testing HIV infected individuals for TB in a low TB/HIV setting. Journal of Infection, 2020, 81, 289-296.	3.3	10
36	The effect of HIV status on the frequency and severity of acute respiratory illness. PLoS ONE, 2020, 15, e0232977.	2.5	6

#	Article	IF	CITATIONS
37	Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea. BMJ Open, 2020, 10, e034098.	1.9	7
38	SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research. Thorax, 2020, 75, 614-616.	5.6	23
39	The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respiratory Medicine,the, 2020, 8, 438-440.	10.7	74
40	Evaluation of QuantiFERON-TB Gold Plus for Predicting Incident Tuberculosis among Recent Contacts: A Prospective Cohort Study. Annals of the American Thoracic Society, 2020, 17, 646-650.	3.2	10
41	A postgraduate qualification in tuberculosis—Message in a bottle. International Journal of Infectious Diseases, 2020, 92, S100-S102.	3.3	1
42	Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respiratory Medicine,the, 2020, 8, 395-406.	10.7	128
43	Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR. Frontiers in Immunology, 2020, 11, 612564.	4.8	16
44	Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 21.	3.8	145
45	Once Daily Versus Overnight and Symptom Versus Physiological Monitoring to Detect Exacerbations of Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial. JMIR MHealth and UHealth, 2020, 8, e17597.	3.7	18
46	Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs. Programme Grants for Applied Research, 2020, 8, 1-76.	1.0	3
47	A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis. , 2020, , .		0
48	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
49	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
50	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
51	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
52	Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohort. Thorax, 2019, 74, 91-94.	5.6	17
53	Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. European Respiratory Journal, 2019, 54, 1900982.	6.7	14
54	Tuberculosis following renal transplantation in England, Wales and Northern Ireland: a national registry-based cohort study. European Respiratory Journal, 2019, 54, 1802245.	6.7	6

#	Article	IF	CITATIONS
55	<global a="" and="" care="" copd:="" health="" in="" methods="" of="" p="" provider="" survey<="" tele-health="" use,="" utility,="">. International Journal of COPD, 2019, Volume 14, 1713-1719.</global>	2.3	15
56	British <scp>HIV</scp> Association guidelines for the management of tuberculosis in adults living with <scp>HIV</scp> 2019. HIV Medicine, 2019, 20, s2-s83.	2.2	8
57	The changing treatment landscape for MDR/XDR-TB — Can current clinical trials revolutionise and inform a brave new world?. International Journal of Infectious Diseases, 2019, 80, S23-S28.	3.3	18
58	Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet, The, 2019, 393, 1216-1224.	13.7	156
59	Revolutionary new treatment regimens for multidrug-resistant tuberculosis. Lancet Infectious Diseases, The, 2019, 19, 233-234.	9.1	5
60	Systematic identification and referral of smokers attending HIV ambulatory care highlights the failure of current service provision in an at-risk population. BMJ Open Respiratory Research, 2019, 6, e000395.	3.0	0
61	New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. Current Opinion in Pulmonary Medicine, 2019, 25, 271-280.	2.6	21
62	Non-tuberculous mycobacterial lung disease in general practice. Practice Nursing, 2019, 30, 432-437.	0.1	0
63	Discordance in latent tuberculosis (TB) test results in patients with end-stage renal disease. Public Health, 2019, 166, 34-39.	2.9	5
64	Clinical utility of existing and second-generation interferon- \hat{I}^3 release assays for diagnostic evaluation of tuberculosis: an observational cohort study. Lancet Infectious Diseases, The, 2019, 19, 193-202.	9.1	47
65	Reducing loss to follow-up during treatment for drug-resistant tuberculosis. European Respiratory Journal, 2019, 53, 1802268.	6.7	5
66	Global Epidemiology of NTM Disease (Except Northern America). Respiratory Medicine, 2019, , 163-260.	0.1	8
67	IMPACT study on intervening with a manualised package to achieve treatment adherence in people with tuberculosis: protocol paper for a mixed-methods study, including a pilot randomised controlled trial. BMJ Open, 2019, 9, e032760.	1.9	7
68	Do higher quantitative interferon gamma release assay or tuberculin skin test results help to predict incident tuberculosis? Data from the UK PREDICT study. , 2019, , .		0
69	Increasing incidence of HIV―associated tuberculosis in Romanian injecting drug users. HIV Medicine, 2018, 19, 316-323.	2.2	4
70	High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population. Thorax, 2018, 73, 557-564.	5.6	29
71	Resilience and Physical and Mental Well-Being in Adults with and Without HIV. AIDS and Behavior, 2018, 22, 1688-1698.	2.7	58
72	Access to influenza immunisation services by <scp>HIV</scp> â€positive patients in the <scp>UK</scp> . Influenza and Other Respiratory Viruses, 2018, 12, 544-546.	3.4	2

#	Article	IF	CITATIONS
73	Update in Tuberculosis and Nontuberculous Mycobacteria 2017. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1248-1253.	5.6	14
74	The duration of protection of school-aged BCG vaccination in England: a population-based case–control study. International Journal of Epidemiology, 2018, 47, 193-201.	1.9	41
75	Prognostic value of interferon-Î ³ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 1077-1087.	9.1	135
76	Can somatic GATA2 mutation mimic germ line GATA2 mutation?. Blood Advances, 2018, 2, 904-908.	5.2	15
77	Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing. Journal of Clinical Microbiology, 2018, 56, .	3.9	131
78	Active case finding and treatment adherence in risk groups in the tuberculosis pre-elimination era. International Journal of Tuberculosis and Lung Disease, 2018, 22, 479-487.	1.2	16
79	Trends in, and factors associated with, HIV infection amongst tuberculosis patients in the era of anti-retroviral therapy: a retrospective study in England, Wales and Northern Ireland. BMC Medicine, 2018, 16, 85.	5.5	5
80	007‣Immunoglobulin G4 related disease with isolated pulmonary involvement in a patient with seropositive rheumatoid arthritis taking adalimumab. Rheumatology, 2018, 57, .	1.9	0
81	High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infectious Diseases, 2018, 18, 206.	2.9	108
82	Hepatitis C among vulnerable populations: A seroprevalence study of homeless, people who inject drugs and prisoners in London. Journal of Viral Hepatitis, 2018, 25, 1260-1269.	2.0	23
83	Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health Technology Assessment, 2018, 22, 1-96.	2.8	24
84	Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice. Thorax, 2017, 72, 180-182.	5.6	24
85	Respiratory symptoms in people living with HIV and the effect of antiretroviral therapy: a systematic review and meta-analysis. Thorax, 2017, 72, 355-366.	5.6	22
86	Respiratory health status is impaired in UK HIVâ€positive adults with virologically suppressed HIV infection. HIV Medicine, 2017, 18, 604-612.	2.2	13
87	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014. Journal of Infection, 2017, 74, 260-271.	3.3	15
88	Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis. European Respiratory Journal, 2017, 50, 1701044.	6.7	13
89	Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV. Aids, 2017, 31, 2403-2413.	2.2	6
90	Treatment of Latent Tuberculosis Infection. Annals of Internal Medicine, 2017, 167, 248.	3.9	149

#	Article	IF	CITATIONS
91	Hepatitis C virus infection in vulnerable populations: a seroprevalence study of homeless, people who inject drugs and prisoners in London, UK. Lancet, The, 2017, 390, S18.	13.7	3
92	Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. European Respiratory Journal, 2017, 50, 1701267.	6.7	26
93	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	37
94	An association between pulmonary Mycobacterium avium-intracellulare complex infections and biomarkers of Th2-type inflammation. Respiratory Research, 2017, 18, 93.	3.6	14
95	S29â \in A randomised controlled trial comparing smartphone enabled remote video observation with direct observation of treatment for tuberculosis. , 2017, , .		0
96	Tuberculosis treatment outcomes among disadvantaged patients in India. Public Health Action, 2017, 7, 134-140.	1.2	17
97	Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. BMC Medicine, 2017, 15, 192.	5.5	12
98	Observational study to estimate the changes in the effectiveness of bacillus Calmette–Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technology Assessment, 2017, 21, 1-54.	2.8	45
99	Evaluation of the GenoType® NTM DR for Subspecies Identification and Determination of Drug Resistance in Clinical M. abscessus Isolates. Clinical Microbiology (Los Angeles, Calif), 2017, 06, .	0.2	0
100	High frequency of unexplained breathlessness among UK HIV positive adults. , 2017, , .		0
101	Personalizing therapy for multidrug resistant TB: the potential of Rapid Whole Genome Sequencing. Expert Review of Anti-Infective Therapy, 2016, 14, 1-3.	4.4	3
102	Determinants of treatment-related paradoxical reactions during anti-tuberculosis therapy: a case control study. BMC Infectious Diseases, 2016, 16, 479.	2.9	42
103	What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax, 2016, 71, 940-949.	5.6	25
104	Headache in an HIV positive patient: diagnostic challenges and approach to treatment. Clinical Medicine, 2016, 16, 548-550.	1.9	6
105	Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance. BMC Medicine, 2016, 14, 117.	5.5	16
106	Occupational Tuberculosis despite Minimal Nosocomial Contact in a Health Care Worker Undergoing Treatment with a Tumor Necrosis Factor Inhibitor. Annals of the American Thoracic Society, 2016, 13, 2275-2277.	3.2	3
107	Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. British Medical Bulletin, 2016, 118, 138-148.	6.9	63
108	A 380-gene meta-signature of active tuberculosis compared with healthy controls. European Respiratory Journal, 2016, 47, 1873-1876.	6.7	51

#	Article	IF	CITATIONS
109	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. European Respiratory Journal, 2016, 48, 1411-1419.	6.7	119
110	Variation in C - reactive protein response according to host and mycobacterial characteristics in active tuberculosis. BMC Infectious Diseases, 2016, 16, 265.	2.9	29
111	Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap. International Journal of Tuberculosis and Lung Disease, 2016, 20, 866-869.	1.2	7
112	Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007–2012. BMC Infectious Diseases, 2016, 16, 195.	2.9	106
113	Uniting to end the TB epidemic: advances in disease control from prevention to better diagnosis and treatment. BMC Medicine, 2016, 14, 47.	5.5	10
114	Clinical Aspects of Adult Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a017848.	6.2	61
115	The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infectious Diseases, The, 2016, 16, 227-238.	9.1	149
116	First independent evaluation of QuantiFERON-TB Plus performance. European Respiratory Journal, 2016, 47, 1587-1590.	6.7	87
117	Respiratory co-morbidities in people with HIV. Lancet Infectious Diseases, The, 2016, 16, 21.	9.1	2
118	The Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra-Pulmonary and Pulmonary Tuberculosis. PLoS ONE, 2016, 11, e0162220.	2.5	81
119	Provision of influenza immunisation for UK HIV positive adults. , 2016, , .		0
120	Attitudes to smoking and quitting in UK HIV positive adults: Would more education help?. , 2016, , .		0
121	CD4+ cell count responses to antiretroviral therapy are not impaired in HIV-infected individuals with tuberculosis co-infection. Aids, 2015, 29, 1363-1368.	2.2	5
122	Commemorating World Tuberculosis Day 2015. International Journal of Infectious Diseases, 2015, 32, 1-4.	3.3	2
123	Collaborative tuberculosis strategy for England. BMJ, The, 2015, 350, h810-h810.	6.0	7
124	Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technology Assessment, 2015, 19, 1-188.	2.8	74
125	Airway bacteria and respiratory symptoms are common in ambulatory HIV-positive UK adults. European Respiratory Journal, 2015, 46, 1208-1211.	6.7	8
126	Shortening treatment of tuberculosis: lessons from fluoroquinolone trials. Lancet Infectious Diseases, The, 2015, 15, 141-143.	9.1	17

#	Article	IF	CITATIONS
127	Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland. Thorax, 2015, 70, 566-573.	5.6	31
128	Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV,the, 2015, 2, e243-e251.	4.7	35
129	Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. International Journal of Infectious Diseases, 2015, 32, 39-45.	3.3	79
130	Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. European Respiratory Journal, 2015, 46, 165-174.	6.7	16
131	Health status and quality of life in tuberculosis. International Journal of Infectious Diseases, 2015, 32, 68-75.	3.3	80
132	Effectiveness of peer educators on the uptake of mobile X-ray tuberculosis screening at homeless hostels: a cluster randomised controlled trial. BMJ Open, 2015, 5, e008050.	1.9	12
133	Identification of the Key Differential Transcriptional Responses of Human Whole Blood Following TLR2 or TLR4 Ligation In-Vitro. PLoS ONE, 2014, 9, e97702.	2.5	17
134	Incidence and risk factors for drug intolerance and association with incomplete treatment for tuberculosis: analysis of national case registers for England, Wales and Northern Ireland, 2001–2010: TableÂ1. Thorax, 2014, 69, 956-958.	5.6	9
135	The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130427.	4.0	75
136	Community-Acquired Pneumonia in HIV-Infected Individuals. Current Infectious Disease Reports, 2014, 16, 397.	3.0	10
137	Managing Pulmonary Nontuberculous Mycobacterial Infection. Time for a Patient-centered Approach. Annals of the American Thoracic Society, 2014, 11, 117-121.	3.2	37
138	Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials. Clinical Infectious Diseases, 2014, 58, 470-480.	5.8	749
139	Universal HIV testing in London tuberculosis clinics: a cluster randomised controlled trial. European Respiratory Journal, 2013, 41, 627-634.	6.7	14
140	Migration and tuberculosis in the UK: targeting screening for latent infection to those at greatest risk of disease: TableÂ1. Thorax, 2013, 68, 1172-1174.	5.6	23
141	Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy. Journal of Crohn's and Colitis, 2013, 7, 412-418.	1.3	20
142	Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infectious Diseases, The, 2013, 13, 529-539.	9.1	243
143	Do we need bacteriological confirmation of cure in uncomplicated tuberculosis?: Table 1–. European Respiratory Journal, 2013, 42, 860-863.	6.7	4
144	Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?: Table 1–. European Respiratory Journal, 2013, 42, 1148-1150.	6.7	28

#	Article	IF	CITATIONS
145	Decreasing incidence of tuberculosis among heterosexuals living with diagnosed HIV in England and Wales. Aids, 2013, 27, 1151-1157.	2.2	18
146	Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. PLoS ONE, 2013, 8, e70630.	2.5	254
147	Evidence for a national problem: continued rise in tuberculosis case numbers in urban areas outside London: Figure 1. Thorax, 2012, 67, 275-277.	5.6	5
148	Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy. PLoS ONE, 2012, 7, e46191.	2.5	190
149	Poor Outcome of Central Nervous System Invasive Aspergillosis in HIV Infection Despite Galactomannan-Based Diagnosis. Infectious Diseases in Clinical Practice, 2011, 19, 299-302.	0.3	1
150	Tuberculosis in the UKtime to regain control. BMJ: British Medical Journal, 2011, 343, d4281-d4281.	2.3	55
151	British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIVâ€seropositive individuals 2011. HIV Medicine, 2011, 12, 1-5.	2.2	99
152	Interferon Â-release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNFÂ therapy. Frontline Gastroenterology, 2011, 2, 26-31.	1.8	3
153	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy, 2011, 66, 1815-1820.	3.0	80
154	A Controlled Trial of the Knowledge Impact of Tuberculosis Information Leaflets among Staff Supporting Substance Misusers: Pilot Study. PLoS ONE, 2011, 6, e20875.	2.5	5
155	Evaluating knowledge gain from TB leaflets for prison and homeless sector staff: the National Knowledge Service TB pilot. European Journal of Public Health, 2008, 18, 600-603.	0.3	8
156	The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999 2003. Thorax, 2007, 62, 672-676.	5.6	43
157	Immune reconstitution inflammatory syndrome in HIV. Current Opinion in Infectious Diseases, 2006, 19, 20-25.	3.1	131
158	HIV and respiratory illness in the antiretroviral therapy era. Annals of Research Hospitals, 0, 1, 43-43.	0.0	0
159	Health economic analyses of latent tuberculosis infection screening and preventive treatment among people living with HIV in lower tuberculosis incidence settings: a systematic review. Wellcome Open	1.8	Ο